Genomics, Biotech, and Emerging Medical Technologies
Rethinking Beta Thalassemia Treatment and Management: Expert Strategies on Novel TherapiesThalassemia describes a hematologic genetic disorder that includes both deletions and mutations of genes involved in hemoglobin production. Hemoglobin, a protein in red blood cells, is responsible for binding to oxygen in the lungs and delivering it to tissues in the body. The hemoglobin protein comprises various chains, including alpha and beta globin chains, which both play an integral role in the proper oxygenation of the body. Chromosome 11 contains genes involved in beta production, and chromosome 16 contains genes related to alpha production. Severity of thalassemia is dependent upon the extent of genetic changes. It represents a growing global health concern, affecting approximately 23,000 births each year. The burden of transfusion-dependent beta thalassemia is profound, with patients experiencing diminished quality of life and hematology teams managing a range of potential complications. Treatment with regular red blood cell transfusions and iron chelation therapy allows for normal growth and development and improves prognosis. Long-term complications associated with iron overload include stunted growth, dilated cardiomyopathy, liver disease, and endocrinopathies. Advances in treatment have improved outcomes for many patients but predicting response to therapy continues to be a big challenge. Managed care clinicians and providers must be educated surrounding recognition of beta thalassemia and early diagnosis, prompt intervention for both acute treatment needs and long-term treatment goals. |
Overcoming Barriers to the Optimal Treatment and Management of Chronic Lymphocytic Leukemia (CLL)Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects older adults. CLL is the most common type of leukemia in adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In 2023, it is expected that there were 20,160 new cases of CLL and about 4,410 deaths, which represents an increase in both numbers. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Fortunately for patients with CLL, several new treatments have recently become available, including BTK inhibitors, giving clinicians many new options to improve patient outcomes with these new treatments and strategies. Additionally, noncovalent BTK inhibitors have recently become available giving managed care professionals even more options to improve outcomes for patients with CLL. This activity focuses on these evolving options and outlines how to incorporate quality measures for the diagnosis and management of CLL and describes how to apply evidence-based data to select appropriate treatment regimens and manage toxicities. With the availability of new treatments, it is critical that physician medical directors, oncologists, nurses and other healthcare professionals are updated on these emerging options, guidelines and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes. |
Developing New Strategies for Diffuse Large B-cell Lymphoma: Incorporating Novel and Emerging Treatments to Improve Long-Term ResultsDiffuse Large B-cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma originating from abnormal B lymphocytes. It is an aggressive blood cancer but can be cured with early detection and treatment. Cancerous white blood cells enlarge lymph nodes and can spread to the spleen, liver, bone marrow, or other organs. In the US, about 20,000 people are diagnosed with DLBCL annually. Symptoms vary depending on the disease’s location and spread in the body. Significant progress has been made in treating DLBCL, allowing many patients to benefit from current treatment options and achieve remission when diagnosed early. Healthcare professionals are continuously exploring new treatment approaches, such as immunotherapies and molecularly targeted therapies. Recently, several new treatments have been introduced for patients with DLBCL, including BTK inhibitors, used both alone and in combination. These novel treatments provide clinicians with various options to enhance patient outcomes. |
Keeping Pace with Rapid Advancements in the Treatment and Management of Gastrointestinal Cancers: Managed Care Insights on the Evolving Role of HER2-Targeting TherapiesGastroesophageal adenocarcinomas (GEA) includes stomach cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. It is the fifth most frequent tumor and the third leading cause of cancer-related deaths worldwide. Despite the prevalence of GEA, the complex nature of these cancers has led to challenges in developing treatment options. As such, the overall prognosis for patients with GEA remains poor, with a global 5-year survival rate of less than 30 percent for gastric cancer and about 19 percent for GEA. Additionally, biliary tract cancer (BTC) is composed of several different types of tumors, each with distinct characteristics that differ based on where they are located within the liver, gallbladder and biliary tract. Rates of BTC are rising quickly in the western world, with a poor prognosis and five-year survival rates under five percent in the metastatic setting. Notably, HER2 overexpression is observed in approximately 20% of these GI cancers and is associated with poor disease outcomes. Fortunately for patients with HER2-positive advanced GEA and BTC, several new agents have been recently approved or are in late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes in the approximately 20% of patients living with HER2-positive GEA and BTC. With these options entering the treatment paradigm, it is critical to provide physician medical directors, oncologists, pharmacy directors and others on the interprofessional management team with updated clinical data and strategies on these new therapies the changing treatment paradigm, with the ultimate goal of improving patient outcomes. |
Copyright permissions
To the best of our knowledge permissions for use of any copyright materials was received by each individual presenter. NAMCP/AAMCN does receive permissions to record, transcribe and publish materials (slides and audio) from each speaker. These permissions are on file at NAMCP headquarters.
For more information contact Jeremy Williams at 804-527-1905 or jwilliams@namcp.org.
Disclaimer
NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.